WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Findings spanned multiple key trials, showcasing TAGRISSO’s effectiveness as both a standalone treatment and in combination therapies.
Data from the Phase III LAURA trial highlighted TAGRISSO’s potential to improve overall survival (OS) in patients with unresectable, Stage III EGFRm NSCLC following chemoradiotherapy. Median OS reached 58.8 months, compared to 54.1 months for placebo, with safety aligning with previous findings. “The continued survival trend in this setting, alongside promising combination data, reinforces osimertinib as an effective and safe treatment for patients across stages of EGFR-mutated lung cancer,” said Dr. Myung-Ju Ahn of Sungkyunkwan University School of Medicine.
The SAVANNAH Phase II trial demonstrated that combining TAGRISSO with savolitinib yielded a 56% objective response rate (ORR) among patients with high MET overexpression and/or amplification after disease progression on TAGRISSO. Median progression-free survival (PFS) reached 7.4 months. Similarly, in the ORCHARD Phase II trial, TAGRISSO paired with datopotamab deruxtecan-dlnk delivered an ORR of up to 43%, with a median PFS of 11.7 months at higher doses.
Additionally, the FLAURA2 Phase III trial confirmed that pairing TAGRISSO with chemotherapy as first-line treatment for advanced EGFRm NSCLC improved PFS. An exploratory analysis confirmed robust benefits, irrespective of chemotherapy maintenance duration.
Susan Galbraith, AstraZeneca’s Executive Vice President of Oncology R&D, noted, “These results underscore TAGRISSO’s ability to extend survival while maintaining quality of life, transforming expectations for patients with EGFR-mutated lung cancer globally.”
TAGRISSO’s breadth of data at ELCC underscores its leading role in enhancing outcomes for patients with EGFR-mutated lung cancers, offering new hope for a population with significant unmet needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.